NCT05077904
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
At risk: Primary completion moved at least 6 months later across 3 updates.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 93 versions: 49 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Site details revised at 1 of 183 sites
- Minor Primary and study completion pushed from Oct 31, 2026 to Mar 29, 2027
- Minor Primary and study completion pushed from Sep 30, 2026 to Oct 31, 2026
- Minor Site details revised at 1 of 183 sitesv90
- Minor Primary and study completion pushed from Aug 31, 2026 to Sep 30, 2026v89
- Minor Site details revised at 2 of 183 sitesv88
- Minor Primary and study completion pushed from Jul 31, 2026 to Aug 31, 2026
- Site details revised at 5 of 183 sites
- Minor Primary and study completion pushed from Jun 30, 2026 to Jul 31, 2026v86
- Minor Site details revised at 5 of 183 sitesv85
- Minor Primary and study completion pushed from Apr 2026 to Jun 30, 2026
- Site details revised at 2 of 183 sites
- Minor Study sites: 182 to 183v83
- Minor Primary and study completion dates: Apr 6, 2026 to Apr 2026v82
- Minor Primary and study completion dates: Apr 2026 to Apr 6, 2026
- Site details revised at 3 of 182 sites
- Minor Primary and study completion dates: Apr 6, 2026 to Apr 2026v80
- Minor Study sites: 181 to 182v79
- Minor Study sites: 180 to 181v78
- Minor Site details revised at 1 of 180 sitesv77
- Minor Site details revised at 1 of 180 sitesv76
- Minor Site details revised at 1 of 180 sitesv75
- Minor Study sites: 177 to 180v74
- Minor Study sites revised (177)v73
- Minor Site details revised at 2 of 177 sitesv72
- Minor Study sites: 175 to 177v71
- Minor Study sites: 174 to 175v70
- Minor Site details revised at 1 of 174 sitesv69
- Minor Study sites: 173 to 174v68
- Minor Study sites: 169 to 173v67
- Minor Study sites: 166 to 169v66
- Minor Study sites: 165 to 166v65
- Minor Study sites: 164 to 165v64
- Minor Study sites: 163 to 164v63
- Minor Study sites: 162 to 163v62
- Minor Site details revised at 1 of 162 sitesv61
- Minor Study sites: 161 to 162v60
- Minor Study sites: 160 to 161v59
- Minor Study sites: 157 to 160v58
- Minor Enrollment target: 250 to 350v57
- Minor Site details revised at 1 of 157 sitesv56
- Minor Study sites: 156 to 157v55
- Minor Study sites: 154 to 156v54
- Notable Primary and study completion dates: Apr 17, 2024 to Apr 6, 2026
- Study sites: 151 to 154
- Minor Site details revised at 2 of 151 sitesv51
- Minor Study sites: 150 to 151v50
- Minor Study sites: 149 to 150v49
- Minor Study sites: 147 to 149v48
- Minor Study sites: 146 to 147v47
- Minor Study sites: 144 to 146v46
- Minor Site details revised at 2 of 144 sitesv45
- Minor Study sites: 143 to 144v44
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Treatment success for the treated seizure within 90 seconds after investigational medicinal product (IMP) administration
Timeframe: From start of IMP treatment through 6 hours
Treatment success for the treated seizure with no recurrence up to 2 hours
Timeframe: From start of IMP treatment through 2 hours
Secondary (6)
Treatment success for treated seizure with no recurrence after 4 hours
Treatment success for treated seizure with no recurrence after 6 hours
Time from IMP administration to cessation of the treated seizure
Frequency of respiratory treatment emergent adverse events (TEAEs)
Number of subsequent seizure(s) up to 2 hours after IMP administration
Show 1 moreShow less
Time to first subsequent seizure up to 2 hours after IMP administration
Arms and interventions
Staccato alprazolam ArmExperimental
Participants randomized to this arm will receive a single dose of Staccato alprazolam by inhalation.
Placebo ArmPlacebo comparator
Participants randomized to this arm will receive a single dose of placebo by inhalation.
Drugs: Staccato alprazolam
Other: Placebo
Sites
183 sites in 13 countries
United States 66, China 33, Japan 21, Poland 9, France 8, Germany 8, Spain 8, Italy 6, United Kingdom 6, Bulgaria 5, Czechia 5, Australia 4, Hungary 4